Dasatinib for Aging

Phase-Based Progress Estimates
Hebrew Senior Life, Boston, MA
Aging+1 More
Dasatinib - Drug
All Sexes
What conditions do you have?

Study Summary

The purpose of this pilot study is to demonstrate the safety and feasibility of administering intermittent doses of Dasatinib and Quercetin (D+Q) in older adults at risk of Alzheimer's disease (AD). The study will evaluate whether giving D+Q may improve cerebral blood flow regulation, mobility, and cognition in older adults, and thus may prevent progression to Alzheimer's disease.

Eligible Conditions

  • Aging

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

3 Primary · 6 Secondary · Reporting Duration: Baseline, 8, and 14 weeks

Week 14
Executive function
Gait speed during cognitive task
Grip strength
Physical performance
Screening and 14 weeks
SASP factors in blood and urine
Senescent CD3 cells expressing p16
Week 14
Gait speed
Neurovascular coupling

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Arm 1
1 of 1
Experimental Treatment

12 Total Participants · 1 Treatment Group

Primary Treatment: Dasatinib · No Placebo Group · Phase 1 & 2

Arm 1Experimental Group · 2 Interventions: Quercetin, Dasatinib · Intervention Types: Drug, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 4
Completed Phase 2

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, 8, and 14 weeks
Closest Location: Hebrew Senior Life · Boston, MA
Photo of Boston 1Photo of Boston 2Photo of Boston 3
N/AFirst Recorded Clinical Trial
1 TrialsResearching Aging
0 CompletedClinical Trials

Who is running the clinical trial?

Lew LipsitzLead Sponsor
Lewis Lipsitz, MDPrincipal InvestigatorHebrew Senior Life
2 Previous Clinical Trials
246 Total Patients Enrolled
1 Trials studying Aging
180 Patients Enrolled for Aging

Eligibility Criteria

Age 65+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have mild cognitive impairment.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.